1 Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated

2 arthritis and preventing relapse during ICI rechallenge: the TAPIR study

Pierre-Florent Petit^{1≠}, Douglas Daoudlarian^{2≠}, Sofiya Latifyan³, Hasna Bouchaab³,
Nuria Mederos³, Jacqueline Doms², Karim Abdelhamid³, Nabila Ferahta³, Lucrezia
Mencarelli², Victor Joo², Robin Bartolini², Athina Stravodimou³, Keyvan Shabafrouz³,
Giuseppe Pantaleo², Solange Peters³, Michel Obeid^{2*}

- 7
- ¹Medical oncology service, CHU Helora, Rue Ferrer 159, 7100 La Louvière, Belgium
- 9 ²Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
- 10 Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne,
- 11 Switzerland
- ¹² ³Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
- 13 Oncology, Medical Oncology Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland
- 14 \neq contributed equally to this work
- 15

16 *Corresponding author:

- 17 Pr Michel Obeid, MD-PhD
- 18 Lausanne Center for Immuno-Oncology Toxicities LCIT
- 19 Immunology and Allergy Division, Rue du Bugnon 17, 1011 Lausanne, Switzerland
- 20 Centre Hospitalier Universitaire Vaudois (CHUV)
- 21 **Email:** michel.obeid@chuv.ch
- 22
- 23 KEY WORDS: immune checkpoint inhibitors, irAEs, arthritis, secondary prophylaxis,
- 24 tocilizumab
- 25
- 26
- 27
- 28

29 Abstract

Background. Immune checkpoint inhibitor (ICI)-associated arthritis (ICI-AR) significantly affects quality of life and often requires discontinuation of ICI therapy and initiation of immunosuppressive treatment. The aim of this retrospective study was to evaluate the dual efficacy of tocilizumab (TCZ), an anti-IL-6R agent, in the treatment of ICI-AR and the prevention of relapses after ICI rechallenge.

35 Methods. This retrospective single-center study was conducted at our institution from 2020 36 to the end of 2023. We identified 26 patients who developed ICI-AR. The primary objectives 37 were to evaluate the therapeutic efficacy of TCZ in the treatment of ICI-AR in 26 patients and 38 to evaluate the potential of TCZ as secondary prophylaxis during ICI rechallenge in 11 of 39 them. For the treatment of ICI-AR, patients received prednisone (CS) at a low dose of 0.3 mg/kg tapered at 0.05 mg/kg weekly for six weeks until discontinuation. TCZ was 40 41 administered at a dose of 8 mg/kg every two weeks. In the subgroup receiving secondary 42 prophylaxis (rechallenge n=11, in 10 patients), TCZ was reintroduced at the same dosage of 8 43 mg/kg bi-weekly concurrently with ICI rechallenge, and without the addition of CS. A control 44 group of patients (rechallenge n=5, in 3 patients) was rechallenged without TCZ. Secondary 45 endpoints included post rechallenge evaluation of ICI duration, reintroduction of CS > 0.146 mg/kg/day, ICI-RA flares, and disease control rate (DCR). An additional explanatory endpoint 47 was the identification of biomarkers predictive of response to TCZ.

Results. The median age of the patients was 70 years. The median follow-up from ICI initiation was 864 days. ICI regimens included anti-PD-(L)1 monotherapy in 17 patients (63%), anti-PD-1 combined with anti-CTLA4 therapy in 8 patients (31%), and anti-PD-1 combined with anti-LAG3 therapy in 1 patient (4%). Among the 20 patients treated with TCZ for ICI-AR, all (100%) achieved an ACR70 response rate, defined as greater than 70%

improvement, at 10 weeks. Additionally, 81% of these patients achieved steroid-free
remission after 24 weeks on TCZ.

55 The median follow-up period was 552 days in rechallenged patients. The ICI rechallenge 56 regimens (n=16) included anti-PD-(L)1 monotherapy in thirteen cases (81%) and combination 57 therapy in three cases (19%). The results demonstrated a reduction in ICI-AR relapses upon 58 ICI rechallenge in patients receiving TCZ prophylaxis as compared to patients who did not 59 receive prophylaxis (17% vs 40%). In addition, the requirement for CS at doses exceeding 0.1 60 mg/kg/day was completely abolished with prophylaxis (0% vs 20%), and the mean duration 61 of ICI treatment was notably extended from 113 days to 206 days. The 12-month post-62 rechallenge outcomes showed a disease control rate (DCR) of 77%. Importantly, during TCZ 63 prophylaxis, CXCL9 levels remained elevated, showing no decline from their levels at the 64 onset of ICI-AR. Additionally, elevations of IL-6 and CXCL10 levels were exclusively 65 observed in patients who developed new irAEs during the period of TCZ prophylaxis.

66 **Conclusion.** In addition to its efficacy in treating ICI-AR, TCZ demonstrated efficacy as a 67 secondary prophylactic agent, preventing the recurrence of ICI-AR symptoms and 68 lengthening ICI treatment duration after ICI rechallenge. The use of TCZ as a secondary 69 prophylaxis may represent a promising strategy to extend patient exposure to ICI treatments 70 and maximize therapeutic benefit.

71

73 Highlights

74	1-	TCZ achieved a 100% ACR70 response rate at 24 weeks, demonstrating its efficacy in
75		the treatment of ICI-RA.
76	2-	A significant 81% of patients achieved steroid-free status after 24 weeks on TCZ,
77		underscoring its utility in accelerating CS tapering.
78	3-	TCZ serves as a successful secondary prophylaxis in patients rechallenged with ICI,
79		preventing significant arthritis flares and the need for additional CS use.
80	4-	TCZ prophylaxis reduces the median time to ICI rechallenge by 47.5 days and extends
81		the duration of uninterrupted ICI therapy by 93 days.
82	5-	CXCL9 levels were not reduced during TCZ prophylaxis, suggesting that there was no
83		negative impact on cytokines associated with oncologic response. In addition, early
84		increases in IL-6 and CXCL10 levels may signal the onset of new irAEs during
85		prophylaxis.

86

87 Introduction

88 Immune checkpoint inhibitor-associated arthritis (ICI-AR) can be persistent and significantly 89 impacts patients' quality of life, necessitating discontinuation of ICI therapy and long-term use of immunosuppressants^{1, 2}. Although clinical trials report arthralgia incidence rates 90 91 ranging from 5 to 11%, expert opinion suggests that these immune-related adverse events (irAEs) may be underreported^{3, 4}. The most common rheumatic (rh) rh-irAEs include 92 inflammatory polyarthritis and polymyalgia rheumatica (PMR)-like syndromes⁵⁻⁷. In contrast 93 to the classical findings observed in patients with rheumatoid arthritis, patients with ICI-AR 94 are rarely positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA)⁴. 95

96 The pathogenesis of ICI-RA remains incompletely understood. The composition of immune 97 cells in the synovial fluid differs significantly from that observed in patients with rheumatoid or psoriatic arthritis⁸. Recent studies have identified a significant clonal expansion of 98 activated effector CD8⁺ T cell populations, including CD38^{hi}CD127⁻ and CXCR3^{hi} subsets in 99 synovial fluid, and CX3CR1^{hi} CD8⁺ T cells in blood^{9, 10}. In contrast to IL-6, levels of IFN-γ, 100 101 TNF- α , and the Th17 signature are reduced in both peripheral blood and synovial fluid following immunosuppressive treatment in ICI-RA patients⁹. However, the precise extent of 102 103 inflammatory cytokine fluctuation relative to baseline levels in cancer patients prior to ICI 104 treatment remains unknown, representing a substantial gap in our data continuum. The lack of 105 comprehensive data on the fluctuations of cytokines limits the identification of reliable biomarkers for the monitoring of ICI-RA progression and the prediction of treatment 106 107 outcomes. Consequently, the establishment of comprehensive baseline and longitudinal 108 cytokines profiling is of paramount importance for the advancement of our understanding and 109 the improvement of ICI-RA management

Tocilizumab (TCZ), an interleukin-6 receptor (IL-6R) inhibitor, is approved for the treatment of many rheumatic diseases, including rheumatoid arthritis, systemic juvenile idiopathic arthritis and giant cell arteritis. It has recently emerged as a promising therapeutic alternative for the treatment of irAEs due to its specificity and potential to attenuate systemic inflammation without suppressing T-cell activity or compromising the anti-tumor immune response¹¹⁻¹³. Recent studies have demonstrated the efficacy of TCZ in the treatment of rheumatoid irAEs while preserving the anti-tumor immune response¹⁴⁻¹⁷.

Furthermore, the incidence of identical irAEs flares following ICI rechallenge exhibits considerable variability, with reported recurrence rates ranging from 18% to 42% across various studies¹⁸⁻²². These relapses can be of increased severity, particularly if the initial irAEs were of high grade. Notwithstanding the difficulties inherent to ICI therapy resumption

121 following severe irAEs, it remains a viable option for a subset of patients who have 122 previously demonstrated a favorable response to ICI retreatment. Our team has previously 123 proposed the use of selective immunosuppression (SI), such as TCZ for arthritis and vedolizumab for colitis, as a secondary prevention when restarting ICI treatment²². Previous 124 125 reports on prophylaxis for ICI-associated colitis have indicated that the recurrence rate of 126 severe ICI-associated colitis following ICI rechallenge was lower in patients receiving prophylaxis with vedolizumab or infliximab compared to those not receiving prophylaxis²³, 127 ²⁴. These preventive approached aim to achieve a balance between efficacy and safety, taking 128 129 advantage of the favorable safety profile of SI to facilitate ICI retreatment. Nevertheless, the 130 efficacy of TCZ as a secondary prophylaxis in the reintroduction of ICI therapy after IRI-RA has not been subjected to a comprehensive evaluation. 131

132 The primary objective of this study is to investigate the dual functionality of TCZ as a 133 treatment of ICI-AR and as a prophylactic agent during subsequent ICI rechallenge. A 134 retrospective analysis was conducted on a cohort of 26 cancer patients diagnosed with ICI-135 AR. This analysis included sequential deep inflammatory profiling of 57 cytokines at four 136 critical time points: baseline prior to the initiation of ICI therapy, at the time of ICI-AR 137 diagnosis, prior to ICI rechallenge, and during ICI rechallenge with TCZ prophylaxis. The 138 data from these patients were compared with those from a larger cohort of cancer patients 139 prior to ICI treatment (n=164) to ascertain inflammatory profiles associated with the onset of 140 ICI-AR and to identify biomarkers predictive of the efficacy of TCZ, both as a treatment and 141 as a prophylactic measure.

142

144 **RESULTS**

145 Clinical demographic and rh-irAE characteristics. A total of 31 patients treated at the 146 Lausanne University Hospital between 2020 and the end of 2023 were identified with rh-147 irAEs following ICI treatment. Of these, 26 patients with ICI-related arthritis (ICI-RA) were 148 included in the final analysis, as described in the study flowchart (Supplementary Figure 1). 149 Patient characteristics are summarized in Table 1. The mean age of the patients was 70 years, 150 with a male predominance (n=15/26, 58%). The most common types of cancer were 151 melanoma and lung cancer, with 11 out of 26 patients (42%) for each tumor type. The 152 majority of the patients were treated with anti-PD-1 monotherapy (n=16/26, 62%) or the 153 combination of nivolumab plus ipilimumab (n=8/26, 31%).

154 The median time from the onset of ICI treatment to the onset of rh-irAEs was 171 days (95% 155 CI: 53-326). The median follow-up period following the initial ICI administration was 864 156 days (95% CI: 576-1152). The median duration of rh-irAEs was 360 days (95% CI:271-546). 157 The most common clinical presentation was polyarticular arthritis (n=14, 54%), while PMR-158 like arthralgia (n=7, 27%) and oligoarticular arthritis (n=5, 19%) were less prevalent. All 159 patients tested negative for rheumatoid factor (RF) and anti-citrullinated protein antibodies 160 (ACPA) (n=0/26, 0%). A history of pre-existing non-active inflammatory rheumatic disease 161 documented in only 20% (n=5/26) of patients, and none were receiving was 162 immunosuppressive drugs (IS) at the time of ICI initiation. A proportion of patients (n=17/26, 163 53%) developed other concomitant immune-related adverse events (irAEs) (Table 1).

164

Tocilizumab is an effective treatment for ICI-AR and allows CS tapering. In the patient
group (n=20/26, 77%) treated with biweekly TCZ at a dosage of 8 mg/kg, in combination
with a low dose of prednisone CS at 0.3 mg/kg/day, 100% of the patients achieved an ACR70

arthritis score²⁵⁻²⁷ (indicating at least 70% improvement from baseline) by weeks 10-12. 168 169 Notably, this rapid improvement was also observed in two patients who received TCZ without 170 CS (n=2/20, 10%). TCZ consistently enabled patients to achieve ACR70 score at both 10-12 171 and 24-weeks following the onset of ICI-AR, as shown in Table 2. 24 weeks (24W) after the 172 introduction of TCZ, 81% of patients (n=13/16) achieved a steroid-free status. The mean CS 173 dose was 23 mg and the average time to reduce CS to less than 10 mg after starting TCZ was 174 30.7 days. The median duration of TCZ treatment was 235 days (95% CI: 55-450). In 175 contrast, those treated with CS alone (n=6) had less favorable outcomes. At 24 weeks, only 176 25% of these patients achieved steroid-free status, compared to 81% in the TCZ-treated 177 group. In addition, this group required a higher mean CS dose of 37.5 mg compared to 23 mg 178 in the TCZ group, and they required longer time - an average of 40.25 days versus 30.7 days -179 to taper their CS dose to below 10 mg (Table 2). This comparison underscores TCZ rapid 180 efficacy in treating ICI-AR and highlights the associated benefits in terms of reducing both 181 CS dosage and treatment duration.

182

183 Tocilizumab prophylaxis facilitates ICI rechallenge and reduces ICI-AR relapse. After 184 completing CS tapering and the resolution of ICI-AR, 13 patients underwent ICI rechallenge, 185 including three undergoing rechallenge twice, for a total of 16 rechallenge episodes (RCLs). 186 TCZ was employed as secondary prophylaxis (TP) in 11 RCLs, while the remaining 5 RCLs 187 proceeded without TCZ prophylaxis (WP). The same ICI was reintroduced in 91% of RCLs 188 (n=10/11) in the TP subgroup, compared to 60% (n=3/5) in the WP subgroup. The median 189 interval between end of initial ICI and ICI rechallenge was 70 days (95% CI:56-84) in the WP 190 group vs 22.5 days (95% CI:20-295) in the TP group, with a median follow-up duration post-191 rechallenge of 498 days (95% CI:341-1040) in the TP group vs 566 days (95% CI:129-757) in

192	the WP group. At the time of ICI rechallenge, oncological disease was progressing in 6
193	cases—40% in the WP subgroup and 36% in the TP subgroup.
194	In the TP subgroup (n=11), the incidence of ICI-AR relapses decreased to 18%, compared to
195	40% in the WP group. Moreover, the requirement for reintroduction of CS at doses exceeding
196	0.1 mg/kg/day dropped to 0% in the TP group versus 20% in the WP group. The mean
197	duration of ICI treatment in the TP group notably extended to 206 days (95% CI:78-333)
198	compared to 113 days (95% CI:16-210) in the WP group. At the last follow-up, ongoing ICI
199	treatment was observed in 36% ($n=4/11$) of the TP group, compared to none in the WP group.
200	In the TP group, the percentage of ICI interruption post-rechallenge due to irAEs was 27%, as
201	opposed to 40% in the WP group. These results are summarized in Table 3.

These results indicate that TCZ prophylaxis can reduce the recurrence of ICI-AR and prevent the escalation of CS use. In addition, TCZ was associated with a shorter interval between initial ICI cessation and ICI rechallenge, and with lower incidence of new irAE development. Consequently, TCZ prophylaxis prolonged the duration of ICI treatment.

206

207 **Oncological outcome and treatment response.** Table 4 describes the oncologic outcome 208 after ICI-RA in patients with definitive ICI discontinuation (n=13). In these patients, the last 209 ICI injection was administered on average 19.6 days after the start of ICI-RA. We observed 210 few cases of progressive disease in these patients (n=1, 8%), while some presented oligo-211 metastatic progression that was treated with local therapy (at 6 months, n=3; at 12 months, 212 n=2). Disease control rates (DCR) were 78% at 6 months and 71% at 12 months in the 213 absence of systemic treatment. We then evaluated the oncological response in rechallenged 214 patients. These patients had worse outcomes after ICI-RA initiation, as 4 patients were 215 rechallenged due to disease progression. Nevertheless, the DCR after rechallenge was 82% at

6 months and 70% at 12 months. The swimmer plot in Figure 1 illustrates ICI treatment andoncological outcomes of patients over time.

Due to the retrospective design of the study, the 2 cohorts (no rechallenge and rechallenge) were biased by oncologist decisions. Patients who develop ICI-RA are commonly associated with a good prognosis. In our cohort, ICI rechallenge was preferentially performed in patients with worse oncologic prognosis, with 4 patients out of 13 patients presenting disease progression at the time of rechallenge initiation (**supplementary Table 1**).

ICI rechallenge was performed with TCZ prophylaxis in 10 of the 13 patients. Oncologic responses were likely achieved due prolonged exposure to ICI treatment. These results underscore the potential of TCZ prophylaxis not only for the management and prevention of ICI-RA, but also for the prolongation of ICI treatment leading to durable disease control.

227

228 A comprehensive profile of cytokine and biological variation. To investigate the 229 inflammatory profile associated with ICI-AR, we evaluated a large spectrum of classical and 230 inflammatory biomarkers prior to the introduction of immunosuppressive therapy. Our analysis focused on the serum levels of 57 cytokines, chemokines, and growth factors. Among 231 232 these, only four-CXCL9, CXCL10, IL-6, and the anti-inflammatory cytokine IL-1RA-233 demonstrated elevated levels at the onset of ICI-AR compared to the baseline levels in cancer 234 patients prior to starting ICI therapy (Figure 2 and supplementary table 2). At the time of 235 rechallenge, after the cessation of CS and TCZ treatment, the levels of CXCL9, CXCL10, and 236 IL-1RA continued to be elevated while levels of IL-6 did not. This pattern suggests a 237 sustained inflammatory response independent of IL-6.

During ICI rechallenge with TCZ prophylaxis, the levels of these cytokines were relatively
stable, consistent with their levels at ICI-AR onset and at RCL baseline. Notably, the levels of

- 240 CXCL10 and IL-6 increased upon emergence of new irAEs following ICI rechallenge under
- 241 TCZ prophylaxis, indicating their potential utility in predicting the development of new irAEs
- despite ongoing TCZ prophylaxis (Figure 2 and supplementary table 2).
- 243
- 244 Figures legend
- 245 Table 1. Clinical, demographic, biological and rh-irAEs characteristics of the ICI-AR
- cohort. The principal clinical, biological, demographic, and rh-irAEs characteristics for the
- 247 ICI-AR cohort (n=26) are detailed in this table.
- 248

249 Table 2. Immunosuppressive treatments and patient responses in the ICI-AR cohort. The 250 different types of immunosuppressive treatment, and symptoms outcomes under treatment in 251 the ICI-AR cohort (n=26) are detailed in this table. 6 patients were treated with CS alone, 18 252 patients were treated with a combination of TCZ 8 mg/kg Q^2w + low dose CS at 0.3 253 mg/kg/day and 2 patients were treated with TCZ 8mg/kg Q2W alone without CS. The 254 ACR50/70 at 10-12w and 24w, the steroid-free status at 24w are detailed. The mean dose of 255 CS and the mean time for <10mg CS in each treatment group are detailed. CS, 256 corticosteroids; TCZ tocilizumab.

257

Table 3. Efficacy of secondary prophylaxis with TCZ in rechallenged patients. The main clinical characteristics and treatment response of the two groups are described, the TCZ secondary prophylaxis (TP) (Rechallenge n=11, in 10 patients) compared to the rechallenged group without TCZ prophylaxis (WP) (Rechallenge n=5, in 3 patients). The median interval between end of initial ICI and rechallenge, the recurrence of rh-irAEs \geq G2, the need for CS>0.1mg/kg/day, the mean duration of ICI treatment and the reason for ICI discontinuation

are detailed. PD; progressive disease, G1 and G2; grade 1 and 2, CRS; cytokine release syndrome, CI confidence interval.

266

Figure 1. Swimmer plot showing duration of oncological response in relationship to duration of ICI treatment and time of ICI rechallenge in the non-rechallenged (n=13) and rechallenged (n=13) groups. Individual swimmer plots for each patient (n=26). CR, complete response, PR, partial response, PD progressive disease, Oligo-PD, oligo-progressive disease. Arrows indicate in progress ICI rechallenge treatment.

Figure 2. Comprehensive cytokine and biological profiles at different timepoints 272 273 compared to cancer patient baseline. (a-f), Evaluation of serum biomarkers in ICI-AR 274 patients at four time points: the time of ICI-RA onset (n=19), ICI rechallenge baseline (n=7), 275 during ICI rechallenge with TCZ prophylaxis (n=6) and at the time of new irAEs during ICI 276 rechallenge under TCZ prophylaxis (n=5) compared to the pre-ICI serum levels in cancer 277 patients before ICI treatment (n=164) used as the reference group. (a-d) serum levels of 278 chemokines, growth factors and cytokines during the four time points. Mann-Whitney U test 279 tests were used to analyze the data for statistical significance between groups. Plots represent 280 values with individual data points, bar represent the mean and error bars represent standard 281 deviation. The results showed a significant difference between the groups with a P-value of 282 less than 0.05 (*), less than 0.01 (**), less than 0.001 (***) and less than 0.0001 (****).

283

284 **Supplementary Figure 1:** Study flowchart.

Supplementary Figure 2: TAPIR retrospective study design, Tocilizumab For Arthritis
Prevention with Rh-irAEs.

287 Supplementary Table 1. Oncological outcomes at 6 and 12 months after initial ICI-RA in

non-rechallenged (n=13) and rechallenged population (n=13), and after ICI rechallenge

in the rechallenged group. The objective response rate (ORR) and disease control rate (DCR) are detailed in the group of patients without ICI rechallenge (n=13) and in the group of patients with ICI rechallenge (n=12, 11 patients on TCZ prophylaxis) 6 and 12 months after the initial ICI-RA. The lower part of the table details disease control rate (DCR) at 6 months and 12 months from rechallenge in the rechallenged group.

Supplementary Table 2. Global cytokine table. Supplementary Table 2. Global cytokine
table. Summary table for 57 cytokine values at four time points: initial rh-irAE onset, before
ICI rechallenge, after rechallenge with TCZ prophylaxis, and at new irAE after rechallenge
with TCZ prophylaxis: N, mean, min, max, percentiles (25th, 50th, 75th) and SD. The lower
limit of detection is included in the table for all cytokines.

299

300 Material and Methods

301 Patient consent, ethical approval and sample collection: All study participants provided 302 informed consent for the research use of their data through a process called "consentement 303 général," which includes coded data handling to ensure confidentiality. For patients who did 304 not actively object, enrollment was facilitated in accordance with Article 34 of the Swiss 305 Federal Law on Human Research. This study was approved by the cantonal ethics committee, formally known as the Commission Cantonale d'Éthique de la Recherche sur l'Être Humain 306 307 (CER-VD). Sample collection: All biological samples were collected during routine clinical 308 practice. No specific interventions or modifications of standard care protocols were performed 309 for the purposes of this study.

310

311 **Patient Cohort**

312 Study design and population. This retrospective study, titled "Tocilizumab for Arthritis 313 Prevention with Rh-irAEs (TAPIR study)," was conducted at the medical oncology and 314 immunology services of the CHUV between 2020 and the end of 2023. It included a cohort of cancer patients treated with ICIs who developed ICI-AR (n=31). 4 patients declined the 315 316 consent, 1 patient transferred to another hospital and only 26 were included in the final 317 analysis, as displayed in the flowchart (Supplemental Figure 1). The primary outcomes were to assess the efficacy of TCZ in treating ICI-AR by evaluating the ACR 20/70 arthritis²⁵⁻ 318 ²⁷ score and to determine its potential as a secondary prophylaxis during ICI re-challenge. 319 320 **Treatment protocol:** TCZ was administered at a dosage of 8 mg/kg biweekly (n=20). 321 Concurrently, patients received low dose of prednisone (CS) at a dosing of 0.3 mg/kg (n=18), 322 which was tapered down by 0.05 mg/kg weekly over a period of 6 weeks, until complete tapering. For those receiving secondary prophylactic treatment (TP) ((Rechallenge n=11, in 323 324 10 patients), TCZ was readministered at the same dosage of 8 mg/kg every two weeks 325 concurrently with the ICI re-challenge treatment, without the introduction of CS. Another 326 group of patients (Rechallenge n=5, in 3 patients) was rechallenged without TCZ (WP) 327 prophylaxis as mentioned in the study design (Supplemental Figure 2). Clinical follow-up. 328 Patients under TCZ treatment continued their routine clinical follow-up. The administration of 329 TCZ did not influence oncological treatment decisions. All decisions regarding the ICI re-330 challenge were made by the referring oncologist. Secondary outcomes. ICI duration post 331 rechallenge, reintroduction of CS >0.1mg/kg/day, ICI-RA flares and the objective response 332 rate (ORR) and disease control rate (DCR)were monitored and recorded following the re-333 challenge with ICI therapy. Explanatory outcomes included biomarker identification that 334 could predict response to TCZ treatment and prophylaxis (Supplemental Figure 2).

Immune profiling of serum biomarkers. As previously described²⁸, serum concentrations of 336 337 cytokines, chemokines, and growth factors were quantified in our study using the Luminex 338 ProcartaPlex immunoassay panel. A comprehensive list of the biomarkers analyzed, their 339 lower limits of detection (LLOD), and the distribution of values within our cohort is provided 340 in Supplementary Table XX. Values recorded below or equal to the LLOD were adjusted to 341 the LLOD to ensure analytical consistency. Our study included a comparative analysis of two 342 different cohorts. In addition to the ICI-associated arthritis (ICI-AR) cohort of 26 patients, we 343 collected baseline serum samples from a large cohort of cancer patients (n=164) prior to ICI 344 treatment to determine pretreatment cytokine levels in a variety of tumor types. Cytokine 345 levels were assessed longitudinally at several critical time points: at the onset of ICI-AR, at 346 the time of ICI rechallenge, and throughout the course of TCZ prophylaxis treatment. This 347 longitudinal approach allowed for a dynamic understanding of how cytokine profiles evolve 348 in response to both disease progression and therapeutic interventions.

Statistical analysis. All statistical analysis in figures comparing cytokines were performed
using GraphPad Prism 10.1.2 (GraphPad Software, Boston, Massachusetts USA).

351

352 **Discussion**

The results of this study indicate that the early introduction of TCZ following the onset of ICI-RA, in conjunction with low-dose CS at 0.3 mg/kg, is highly effective for the treatment of ICI-RA, thereby eliminating the need for higher CS dosages. At 10 weeks, a 100% ACR70 response rate was achieved, with 81% of patients attaining CS-free remission after 24 weeks. These results are of particular significance as they demonstrate the rapid resolution of arthritis under TCZ, with a remarkable 70% symptom reduction within just 10 weeks of treatment across all participants. These outcomes represent a significant advancement over previous

360 reports, as they establish a clear timeframe—24 weeks—for achieving steroid-free remission,

361 a detail often omitted in earlier studies.

This strategy not only rapidly alleviates arthritis symptoms but also significantly improves the possibility of CS tapering. In particular, the duration to obtain CS<10mg was reduced by 24% compared to the CS group and by more than 50% compared to previous studies, which often reported treatment durations exceeding several months^{1, 2, 4, 5}. The mean CS dose (mg) was reduced by 39% compared to the CS group. These results highlight TCZ's potential to streamline and optimize arthritis treatment, reducing both the dose and the duration of CS treatment.

Another significant finding of this study was the absence of arthritis flares or the need for CS during rechallenge with ICIs when TCZ was used as a prophylactic agent. This outcome is of particular significance as it addresses an important challenge in the management of patients who have a history of ICI-RA. Typically, the recurrence of arthritis has constituted an obstacle to the continuation of potentially life-saving therapy. Our report underscores the efficacy of TCZ in preventing arthritis flares.

375 CS are frequently employed to address irAEs, but their immunosuppressive impact can 376 diminish the advantages of ICIs²⁹⁻³¹ and introduce complexities in long-term management due 377 to their adverse effects. By reducing the necessity for CS in the treatment of ICI-RA, and by 378 preventing the need for CS after ICI rechallenge, TCZ may help to preserve the integrity of 379 the immune response initiated by ICIs, which is crucial for achieving optimal therapeutic outcomes. Moreover, as previously documented, IL-6 functions as a protumoral cvtokine³². 380 381 Consequently, the use of an anti-IL-6 strategy presents a dual benefit: firstly, it mitigates the 382 adverse effects of CS and secondly, it enhances ICI efficacy by promoting Th1 polarization, thereby optimizing the therapeutic impact of ICIs³³⁻³⁶. 383

It is important to note that the use of TCZ as secondary prophylaxis significantly extended the duration of ICI administration, allowing re-administration for an average of 7.2 months compared to only 3.7 months without prophylaxis. In addition, TCZ prophylaxis significantly shortened the time to ICI rechallenge after initial discontinuation by a factor of 3.11, reducing the interval from 70 days to 22.5 days. At last follow-up, ongoing ICI use was 36% in the TCZ group (TP) versus 0% in the non-prophylaxis group (WP).

390 This is a retrospective study with a small number of patients and it does not allow statistical 391 comparisons between patient groups. Importantly, the decision to rechallenge with ICI was 392 made by oncologists based on evidence of disease progression or a perceived increased risk of 393 progression. Consequently, these two groups of patients are distinct and cannot be directly 394 compared. Nevertheless, we observed a sustained DCR in patients rechallenged with ICI 395 under TCZ prophylaxis, even in patients presenting disease progression at rechallenge 396 initiation. This finding is important because it demonstrates that TCZ prophylaxis may 397 facilitate long-term use of ICIs and achievement of oncologic control, potentially improving 398 overall survival (OS).

Our report suggests that TCZ can be effectively incorporated into the arthritis treatment regimen at an early stage and maintained without interruption of ICI therapy as a secondary prevention strategy. These results, among the first of their kind, set a new precedent for the management of ICI-RA and have the potential to significantly change current therapeutic paradigms by providing a more continuous and potentially more effective treatment pathway for patients undergoing ICI therapy.

This secondary prevention strategy, which involves the administration of TCZ following the onset of irAEs, contrasts with primary prevention, where TCZ is given preemptively to mitigate the frequency and severity of irAEs³⁷. The determination of the most efficacious approach, whether primary or secondary prevention, requires further research. This necessity

is further reinforced by the mounting body of evidence linking the occurrence of irAEs to the efficacy of ICI treatments³⁸⁻⁴¹ and numerous studies that have reported elevated IL-6 levels during irAE episodes^{42, 43}. Furthermore, the intricate network of cytokines may result in unfavorable outcomes when IL-6 signaling is blocked in the initial stages following the initiation of ICI therapy⁴⁴. Accordingly, a more comprehensive investigation into the optimal timing for preventive strategies is of critical importance in this field.

415 In this study, we analyzed the levels of 57 cytokines at the onset of ICI-RA prior to the 416 initiation of immunosuppressive (IS) treatment and compared these levels with baseline 417 measurements in a cohort of cancer patients prior to ICI treatment (n=164). The increase in 418 pro-inflammatory cytokines was limited to IL-6, CXCL9, CXCL10, and IL-RA. Other 419 cytokine, chemokine and growth factor profiles remained stable. Notably, all patients with 420 ICI-RA showed a consistent increase in IL-6 compared to baseline, without the concomitant 421 increase in other inflammatory cytokines typically associated with inflammatory arthritis, such as IL-17⁴⁵, IL-21⁴⁶ and IL-22⁴⁷. IL-6 levels continued to increase during TCZ treatment, 422 as expected, and consistent with previous reports^{11-13, 48, 49}. This distinct cytokine profile 423 highlights the unique inflammatory pathway activated in ICI-RA and underscores the 424 425 potential for therapeutic targeting of IL-6 in this context. Notably, while previous studies have 426 reported the use of anti-IL-6 receptor therapy for the treatment of ICI-RA^{17, 50}, they have not investigated longitudinal changes in cytokine levels. Our study fills this gap by assessing 427 428 these variations, providing a deeper understanding of cytokine dynamics over the course of 429 treatment and highlighting the potential importance of these changes in guiding therapeutic 430 decisions. This approach not only validates the role of IL-6, but also suggests the utility of 431 monitoring cytokine profiles as a component of personalized treatment strategies.

It is noteworthy that we observed an increase in CXCL9 levels during TCZ prophylaxis,similar to the levels observed at the onset of ICI-RA. This increase is clinically significant, as

434 previously reported, as elevated serum CXCL9 during ICI-RA correlates with favorable oncological outcomes⁵¹. Furthermore, intratumoral increases in CXCL9, a chemokine 435 436 essential for immune cell recruitment, have been associated with enhanced therapeutic responses in patients undergoing ICIs⁵². During TCZ prophylaxis, the stability of CXCL9 437 438 levels suggests that the inflammatory and immune-stimulatory milieu necessary for ICI 439 efficacy is maintained. The non-reduction of CXCL9 levels suggest that, despite the 440 immunosuppressive action of TCZ (which is primarily aimed at IL-6 blockade), the immune 441 system's ability to recruit T cells against the tumor remains active. This is of significant 442 importance as it indicates that the prophylactic use of TCZ does not impede the primary anti-443 tumor immune response facilitated by ICIs. This is a significant concern when integrating any 444 form of immunosuppression in cancer therapy. Monitoring CXCL9 levels may therefore prove to be a valuable biomarker for assessing the real-time efficacy of ICI therapy. By 445 446 identifying and monitoring such cytokine surges, clinicians can better predict treatment responses and tailor therapeutic strategies, thereby optimizing patient outcomes. This 447 448 approach capitalizes on the dual benefits of TCZ-managing arthritis and boosting ICI 449 efficacy—through a deeper understanding of cytokine dynamics during treatment. The 450 investigation of cytokine behavior in this context is of paramount importance and requires 451 comprehensive investigation and validation to enhance our understanding of how immune 452 modulation by TCZ impacts the success of cancer immunotherapy.

The observed increase in IL-6 and CXCL10 during new irAEs under TCZ prophylaxis suggest that IL-6 and CXCL10 warrant close monitoring, as they may signal the emergence of new irAEs. By allowing earlier detection, these biomarkers might prompt investigations and targeted interventions.

457 Although the initial results of our study are encouraging, several limitations must be 458 acknowledged. First, the results are retrospective data derived from a single center with a

459 relatively small cohort, which limits the generalizability of the results to different clinical 460 settings. In addition, the study may lack diversity in patient demographics such as age, sex, 461 ethnicity, and underlying health conditions, which may affect the applicability of the findings 462 to broader populations. The potential retrospective design of the study also introduces 463 inherent biases, such as selection bias and confounding factors, which require randomized 464 controlled trials with large control arm without TCZ prophylaxis. Finally, more 465 comprehensive studies are warranted to explore how modulation of immune responses by 466 TCZ affects long-term oncologic efficacy.

In conclusion, this study suggests that TCZ is a viable strategy for both the treatment and prevention of ICI-RA upon ICI rechallenge. This dual efficacy of TCZ could significantly change the therapeutic landscape for patients undergoing ICI therapy who are at risk of, or have experienced, ICI-RA. By facilitating the broader use of ICIs in cancer patients, TCZ could ensure that a greater number of patients benefit from potent immunotherapy potentially improving patient outcomes by maintaining uninterrupted and effective ICI treatment.

473 Acknowledgements

This work was supported by the strategic plan of the CHUV. We would like to express our
gratitude to all the patients who generously contributed their time and samples for this project.
We thank Pr Gérard Waeber for his advice. Visual abstract was created with BioRender.com.

477

478 Author contributions

MO conceived and designed the study. MO and PFP drafted the manuscript. MO, PFP and
DD had full access to all data in the study and take responsibility for its integrity and
accuracy.

482	DD, PFP and MO collected the data. PFP, DD and MO analyzed and interpreted the data. VJ
483	and RB realized the cytokine data. SL, HB, NM, KA, JD, NF, LM, AS, KS and SP
484	participated in the clinical treatments. PFP, DD and MO prepared the figures. SP. and GP
485	participated in scientific discussion. The manuscript was reviewed and approved by all
486	authors before submission.
487	
488	Conflict of interest
489	MO received honoraria and speaker fees from Moderna, Roche and BMS.
490	Data sharing statements
490 491	Data sharing statements The datasets supporting the results of this study are not publicly available. Requests for access
491	The datasets supporting the results of this study are not publicly available. Requests for access
491 492	The datasets supporting the results of this study are not publicly available. Requests for access to the dataset will be granted upon reasonable request to the principal investigator. Study data
491 492 493	The datasets supporting the results of this study are not publicly available. Requests for access to the dataset will be granted upon reasonable request to the principal investigator. Study data will be managed, stored, shared, and archived according to CHUV standard operating

498 **References**

499	1	Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors:
500	•	epidemiology, management and surveillance. Nat Rev Clin Oncol 2019.
501	2	Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from
502	_	cancer immunotherapy. Nat Rev Rheumatol 2018; 14 (10): 569-579.
503	3	Belkhir R, Burel SL, Dunogeant L et al. Rheumatoid arthritis and polymyalgia rheumatica
504		occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 2017; 76 (10): 1747-
505		1750.
506	4	Braaten TJ, Brahmer JR, Forde PM et al. Immune checkpoint inhibitor-induced inflammatory
507		arthritis persists after immunotherapy cessation. Ann Rheum Dis 2020; 79 (3): 332-338.
508	5	Ghosh N, Tiongson MD, Stewart C et al. Checkpoint Inhibitor-Associated Arthritis: A
509		Systematic Review of Case Reports and Case Series. J Clin Rheumatol 2021; 27 (8): e317-
510		e322.
511	6	Calabrese C, Cappelli LC, Kostine M et al. Polymyalgia rheumatica-like syndrome from
512		checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open
513		2019; 5 (1): e000906.
514	7	Martin de Fremont G, Belkhir R, Henry J et al. Features of polymyalgia rheumatica-like
515		syndrome after immune checkpoint inhibitor therapy. Ann Rheum Dis 2022; 81 (3): e52.
516	8	Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory
517		arthritis. Curr Opin Rheumatol 2020; 32 (3): 315-320.
518	9	Kim ST, Chu Y, Misoi M et al. Distinct molecular and immune hallmarks of inflammatory
519		arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 2022; 13
520		(1): 1970.
521	10	Wang R, Singaraju A, Marks KE et al. Clonally expanded CD38(hi) cytotoxic CD8 T cells
522		define the T cell infiltrate in checkpoint inhibitor-associated arthritis. Sci Immunol 2023; 8
523		(85): eadd1591.
524	11	Doms J, Prior JO, Peters S et al. Tocilizumab for refractory severe immune checkpoint
525		inhibitor-associated myocarditis. Ann Oncol 2020; 31 (9): 1273-1275.
526	12	Moi L, Bouchaab H, Mederos N et al. Personalized Cytokine-Directed Therapy With
527		Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. J
528		Thorac Oncol 2021; 16 (2): 318-326.
529	13	Ozdemir BC, Latifyan S, Perreau M et al. Cytokine-directed therapy with tocilizumab for
530		immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. Ann Oncol 2020;
531		31 (12): 1775-1778.
532	14	Kim ST, Tayar J, Trinh VA et al. Successful treatment of arthritis induced by checkpoint
533		inhibitors with tocilizumab: a case series. Ann Rheum Dis 2017; 76 (12): 2061-2064.
534	15	Holmstroem RB, Nielsen OH, Jacobsen S et al. COLAR: open-label clinical study of IL-6
535		blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis
536		and arthritis. J Immunother Cancer 2022; 10 (9).
537	16	De La Fuente F, Belkhir R, Henry J et al. Use of a bDMARD or tsDMARD for the
538		management of inflammatory arthritis under checkpoint inhibitors: an observational study.
539		RMD Open 2022; 8 (2).
540	17	Fa'ak F, Buni M, Falohun A et al. Selective immune suppression using interleukin-6 receptor
541		inhibitors for management of immune-related adverse events. J Immunother Cancer 2023; 11
542		(6).
543	18	Nakajima EC, Lipson EJ, Brahmer JR. Challenge of Rechallenge: When to Resume
544		Immunotherapy Following an Immune-Related Adverse Event. J Clin Oncol 2019; 37 (30):
545		2714-2718.
546	19	Pollack MH, Betof A, Dearden H et al. Safety of resuming anti-PD-1 in patients with immune-
547		related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic
548		melanoma. Ann Oncol 2018; 29 (1): 250-255.

549	20	Simonaggio A, Michot JM, Voisin AL et al. Evaluation of Readministration of Immune
550		Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA
551	0.1	Oncol 2019; 5 (9): 1310-1317.
552	21	Dolladille C, Ederhy S, Sassier M et al. Immune Checkpoint Inhibitor Rechallenge After
553	22	Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol 2020; 6 (6): 865-871.
554	22	Haanen J, Ernstoff M, Wang Y et al. Rechallenge patients with immune checkpoint inhibitors
555		following severe immune-related adverse events: review of the literature and suggested
556	22	prophylactic strategy. J Immunother Cancer 2020; 8 (1).
557	23	Badran YR, Cohen JV, Brastianos PK et al. Concurrent therapy with immune checkpoint
558		inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse
559	24	events. J Immunother Cancer 2019; 7 (1): 226.
560	24	Badran YR, Zou F, Durbin SM et al. Concurrent immune checkpoint inhibition and selective
561		immunosuppressive therapy in patients with immune-related enterocolitis. J Immunother
562	25	Cancer 2023; 11 (6).
563	25	Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary
564 565	26	definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38 (6): 727-735.
565 566	20	van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement
567	27	criteria that include simplified joint counts. Arthritis Rheum 1998; 41 (10): 1845-1850. Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include
568	21	twenty-eight-joint counts. Development and validation in a prospective longitudinal study of
569		patients with rheumatoid arthritis. Arthritis Rheum 1995; 38 (1): 44-48.
570	28	Noto A, Joo V, Mancarella A et al. CXCL12 and CXCL13 Cytokine Serum Levels Are
570 571	20	Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. Viruses
572		2022; 14 (12).
573	29	Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of
574	29	glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011;
575		335 (1): 2-13.
576	30	Libert C, Dejager L. How steroids steer T cells. Cell Rep 2014; 7 (4): 938-939.
577	31	Giles AJ, Hutchinson MND, Sonnemann HM et al. Dexamethasone-induced
578	51	immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer
579		2018; 6 (1): 51.
580	32	Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor
581		microenvironment. Semin Immunol 2014; 26 (1): 38-47.
582	33	Tsukamoto H, Fujieda K, Miyashita A et al. Combined Blockade of IL6 and PD-1/PD-L1
583		Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor
584		Microenvironment. Cancer Res 2018; 78 (17): 5011-5022.
585	34	Mace TA, Shakya R, Pitarresi JR et al. IL-6 and PD-L1 antibody blockade combination
586		therapy reduces tumour progression in murine models of pancreatic cancer. Gut 2018; 67 (2):
587		320-332.
588	35	Ohno Y, Toyoshima Y, Yurino H et al. Lack of interleukin-6 in the tumor microenvironment
589		augments type-1 immunity and increases the efficacy of cancer immunotherapy. Cancer Sci
590		2017; 108 (10): 1959-1966.
591	36	Huseni MA, Wang L, Klementowicz JE et al. CD8(+) T cell-intrinsic IL-6 signaling promotes
592		resistance to anti-PD-L1 immunotherapy. Cell Rep Med 2023; 4 (1): 100878.
593	37	J.S. Weber TM, O. Hamid, J. Mehnert, F.S. Hodi, S. Krishnarajapet, S. Malatyali, E.
594		Buchbinder, J. Goldberg, R. Sullivan, M. Faries, I. Mehmi. Phase II trial of ipilimumab,
595		nivolumab and tocilizumab for unresectable metastatic melanoma. Annals of Oncology 2021.
596	38	Shankar B, Zhang J, Naqash AR et al. Multisystem Immune-Related Adverse Events
597		Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung
598		Cancer. JAMA Oncol 2020; 6 (12): 1952-1956.
599	39	Hu W, Wang G, Wang Y et al. Uncoupling Therapeutic Efficacy from Immune-Related
600		Adverse Events in Immune Checkpoint Blockade. iScience 2020; 23 (10): 101580.
601	40	Hua C, Boussemart L, Mateus C et al. Association of Vitiligo With Tumor Response in
602		Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol 2016; 152
603		(1): 45-51.

604 605 606	41	Fujii T, Colen RR, Bilen MA et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 2018; 36 (4): 638-646.
607 608 609 610	42	Yu Y, Wang S, Su N et al. Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Front Oncol 2022; 12: 906824.
611 612 613	43	Zhang X, Lu X, Yu Y et al. Changes of IL-6 And IFN-gamma before and after the adverse events related to immune checkpoint inhibitors: A retrospective study. Medicine (Baltimore) 2022; 101 (46): e31761.
614 615	44	Wei F, Sasada T. Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes Immun 2024; 25 (1): 89-91.
616 617	45	Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 2009; 11 (5): 365-370.
618 619	46	Agonia I, Couras J, Cunha A et al. IL-17, IL-21 and IL-22 polymorphisms in rheumatoid arthritis: A systematic review and meta-analysis. Cytokine 2020; 125: 154813.
620 621	47	Aarts J, Roeleveld DM, Helsen MM et al. Systemic overexpression of interleukin-22 induces the negative immune-regulator SOCS3 and potently reduces experimental arthritis in mice.
622	40	Rheumatology (Oxford) 2021; 60 (4): 1974-1983.
623 624	48	Sun X, Fang C, Jin S et al. Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis. Eur J Intern Med 2024.
625 626	49	Horisberger A, La Rosa S, Zurcher JP et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 2018; 6
627		(1): 156.
628 629 630	50	Bass AR, Abdel-Wahab N, Reid PD et al. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 2023; 82 (7): 920-926.
631 632 633 634 635 636	51	Michel Obeid VJ, Douglas Daoudlarian, Robin Bartolini, Hasna Bouchaab, Sofiya Latifyan, Nuria Mederos, Karim Abdelhamid, Valérie Mosimann, Nabila Ferahta, Keyvan Shabafrouz, Giuseppe Pantaleo, and Solange Peters. High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response. Journal of Clinical Oncology 2024.
637 638 639	52	House IG, Savas P, Lai J et al. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res 2020; 26 (2): 487-504.





Figure 2




	n = 26	% within cohort
Age		
Mean at rh-irAE onset	70	95% CI:63-77
Corhort follow-up (median, days)		
Follow-up from ICI initiation	864.5	95% CI:576-1152
Follow-up from rh-irAE	564	95% CI: 384-825
<u>rh-irAEs onset</u>		
Median time of onset (days)	171	95% CI:53-326
Onset within 90 days	11	42%
rh-irAEs clinical presentation		
Polyarticular arthritis (>5 joints)	14	54%
PMR-like	7	27%
Oligo-arthritis (<5 joints)	5	19%
Rh-irAE duration (median, days)		
Rh-irAE duration	360	95% CI:271-546
Biological findings		
<u>Rheumatoid factor (RF)</u>		
Tested positive	0/26	0%
ACPA		
Tested positive	0/26	0%
Gender		
Male	15	58%
Female	11	42%
Tumor type		
Melanoma	11	42%
Lung	11	42%
Head and neck	2	8%
Colorectal	1	4%
Renal cell carcinoma	1	4%
Initial ICI therapy		
Nivolumab/ipilimumab	8	31%
Nivolumab/relatlimab	1	4%
Anti PD-1 monotherapy	16	62%
Anti PD-L1 monotherapy	1	4%
Pre-existing rheumatic diseases		
Polymyalgia rheumatica	3	12%
Seronegative polyarthritis	1	4%
Axial spondyloarthritis	1	4%
Concomitant irAE		
Colitis	3	12%
Cutaneous	2	8%
Hepatitis	2	8%
Endocrine	4	15%
Pneumonitis	1	4%
Myositis	2	8%

	n = 26	% within cohort		
Immunosupressive treatment				
1L corticosteroids (CS) alone	e 6	23%		ļ
1L tocilizumab (TCZ) + CS	18	69%		ļ
1L TCZ Alone	2	8%		/
Response to treatment	with TCZ n = 20 (78%)	%	with CS n=6 (22%)	%
ACR50 at W10-12	20 out of 20	100%	6 out of 6	100%
ACR70 at W10-12	20 out of 20	100%	6 out of 6	100%
ACR70 at W24	16 out of 16	100%	4 out of 4	100%
Steroid-free 24W	13 out of 16	81%	1 out of 4	25%
Treatment characteristics				
Mean CS dose (mg)	23		37.5	
Time for <10mg CS (mean days)	N/A		40.25	
Time for <10mg CS after TCZ (mean days)	30.7		N/A	
TCZ duration (median days)	235		N/A	

	Without TCZ Prophylaxis		With TCZ Prophylaxis	
	n = 5	%	n = 11	%
Patients with >1 rechallenge	2	40%	1	9%
Median Interval between end of intial ICI and rechallenge	70	95% CI:56-84	22.5	95% CI:20-295
Rechallenge for PD	2	40%	4	36%
Tumor type				
Lung	2	67%	5	50%
Melanoma	1	33%	4	40%
Colorectal	0	0%	1	10%
Rechallenge as compared to initial ICI therapy				
Similar ICI	3	60%	10	91%
Nivolumab to ipilimumab/nivolumab	0	0%	1	9%
Nivolumab to pembrolizumab/chemotherapy	1	20%	0	0%
Nivolumab to nivolumab/relatlimab	1	20%	0	0%
rh-irAE evolution				
Requiring steroids >0.1 mg/kg for Arthritis	1	20%	0	0%
Relapse rh-irAE ≥ G2	2	40%	2	18%
Other irAEs				
 Colitis ≥ G2	1	20%	5	45%
CRS G1	0	0%	1	9%
Pneumonitis	1	20%	0	0%
ICI rechallenge interruption				
Due to rh-irAEs flares	0	0%	0	0%
Due to others irAEs types	2	40%	3	27%
Due to disease control	1	20%	1	9%
Due to neutropenia	0	0%	1	9%
Due to end of adjuvant treatment	0	0%	1	9%
Due to PD	2	40%	0	0%
Patient decision	0	0%	1	9%
ICI treatment duration				
Mean duration (days)	113	95% CI:16-210	206	95% CI:78-333
ICI > 90 days	2	40%	6	55%
Ongoing ICI at least follow-up	0	0%	4	36%
Median follow up after rechallenge (days)	566	95% CI:129-757	498	95% CI:341-1040

		Patient without ICI rechallenge (n=13)		Patient with ICI rechallenge (n=13)	
Oncological outcome 6 months after initial rh-irAE					
Complete Response (CR)	1	8%	3	23%	
Partial Response (PR)	3	23%	3	23%	
Adjuvant no PD	3	23%	2	15%	
Oligo-PD	3	23%	2	15%	
PD	1	8%	3	23%	
Death	1	8%	0	0%	
Unknown	1	8%	0	0%	
Disease Control Rate (DCR)	7	78%	8	73%	
Oncological outcome 12 months after initial rh-irAE					
Complete Response (CR)	1	8%	4	31%	
Partial Response (PR)	2	15%	2	15%	
Adjuvant no PD	3	23%	2	15%	
Oligo-PD	2	15%	2	15%	
PD	0	0%	2	15%	
Death	2	15%	1	8%	
Unknown	3	23%	0	0%	
Disease Control Rate (DCR)	5	71%	8	73%	
Oncological outcome 6 months after ICI rechallenge			n=11		
Complete Response (CR)			4	36%	
Partial Response (PR)			3	27%	
Stable Disease (SD)			2	18%	
Progressive Disease (PD)			1	9%	
Death			1	9%	
Disease Control Rate (DCR)			9	82%	
Oncological outcome 12 months afer ICI rechallenge			n=10		
Complete Response (CR)			6	60%	
Partial Response (PR)			1	10%	
Stable Disease (SD)			0	0%	
Progressive Disease (PD)			2	20%	
Death			1	10%	
Disease Control Rate (DCR)			7	70%	



TAPIR Retrospective Study Design (Tocilizumab For Arthritis Prevention with Rh-irAEs)

